Synopsis:- Backed by a blockbuster Q4 FY26 performance that saw net profit jump 154 percent year-on-year, Morgan Stanley has maintained its ‘Overweight’ rating on Bharat Heavy Electricals and raised its price target to ₹444, implying nearly 20 percent...
SYNOPSIS: Mid-Cap shares are in focus after Q4 results, with revenue up 73.8% YoY to ₹1,175 crores and net loss narrowing to ₹100 crores. HSBC and Nomura maintained their Buy ratings on the stock. The shares of a Mid-Cap company specialising in the design,...
Synopsis: A domestic brokerage has maintained a ‘Buy’ call on a leading retail-focused NBFC, pointing to a strong earnings recovery, gold loan dominance, and improving asset quality as reasons to stay optimistic. After a period of regulatory headwinds and...
Synopsis: Petronet LNG offers strong upside potential with target prices of Rs. 335-400, supported by earnings growth and recovery prospects, though utilization concerns may limit near-term stock movement. This Mid-Cap Stock, engaged in importing, regasifying,...
Synopsis: Bengaluru-based IT services company has turned the corner on revenue growth after a string of strong deal wins, and one brokerage sees the momentum only building from here, setting a target that implies significant upside for investors. After months of...
Synopsis: A leading private lender posts strong loan and deposit growth in Q4FY26, but core profitability disappoints – and a top brokerage still sees room to run. This large-cap Bank’s fourth quarter results for FY26 presented a split picture, robust business...
Synopsis: Shares of InterGlobe Aviation (IndiGo) may remain in focus after Morgan Stanley retained an Overweight rating. While rising ATF prices and currency pressure may weigh on near-term margins, brokerages expect IndiGo’s scale, cost efficiency, and balance sheet...
Synopsis: Brokerages are bullish on select stocks across sectors, citing strong growth visibility and earnings momentum, with potential upside of up to 62 percent driven by improving demand and valuations Brokerage firms have turned bullish on a set of stocks across...
Synopsis: Nomura sees about 21 percent upside in Dr Reddy’s, driven by early generic entry, a $1 billion opportunity, and biosimilar pipeline, despite near-term margin pressure and earnings decline. The article outlines the rationale behind Nomura’s Bullish views on...
